Bevacizumab Improves Survival in Metastatic Colorectal Cancer Patients With Primary Tumor Resection: A Meta-Analysis

Scientific Reports - United Kingdom
doi 10.1038/s41598-019-56528-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Frontiers in Oncology
Cancer ResearchOncology
2019English

Resection of the Primary Tumor Improves Survival in Metastatic Breast Cancer by Reducing Overall Tumor Burden

Surgery
Surgery
2013English

Palliative Resection of a Primary Tumor in Patients With Unresectable Colorectal Cancer: Could Resection Type Improve Survival?

Annals of Surgical Treatment and Research
Surgery
2016English

Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Hypertension and Overall Survival in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Containing Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2011English

Effect of Application and Intensity of Bevacizumab-Based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-Analysis

Clinical Colorectal Cancer
OncologyGastroenterology
2016English

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis

Oncologist
Cancer ResearchMedicineOncology
2017English

The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival

Annals of Surgical Oncology
OncologySurgery
2019English

Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy